Loading stock data…
ULBI
$6.50-0.15 (-2.33%)
Market OpenUpdated 3:46 PM EDT
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ultralife Corporation in the Industrials sector is trading at $6.50 with a market capitalization of $115M. The stock is currently 32% below its 52-week high of $9.52, remaining 0.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.50
Potential Downside
0%
Whystock Fair Value$6.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Syste...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$115.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.34%
Volume
Today's trading volume
33,410
Recent News
Ultralife (ULBI) Q1 2026 Earnings Transcript
Before turning the call over to management, I would like to remind everyone that some statements made during this conference call contain forward-looking statements based on current expectations. The company cautions investors not to place undue reliance on forward-looking statements, which reflect the company's analysis only as of today's date. The company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances.
Undervalued Small Caps With Insider Buying Across Regions
The United States market has experienced a flat week, yet it has shown a robust 27% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of growth and stability, identifying stocks that are currently undervalued can offer potential opportunities for investors seeking to capitalize on insider confidence and regional strengths.
Undervalued Small Caps With Insider Activity To Consider In May 2026
Over the last 7 days, the United States market has risen by 2.6%, contributing to a significant 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this environment of robust growth, identifying small-cap stocks that are potentially undervalued and exhibit insider activity can be an intriguing opportunity for investors seeking value in a dynamic market landscape.
Ultralife Corp (ULBI) Q1 2026 Earnings Call Highlights: Record Backlog Amid Revenue Challenges
Despite a challenging quarter with revenue declines, Ultralife Corp (ULBI) focuses on strategic growth initiatives and reports a record backlog of $115.1 million.
Ultralife Q1 Earnings Call Highlights
Ultralife (NASDAQ:ULBI) reported a first-quarter loss for fiscal 2026 as lower sales, production disruptions and higher one-time costs weighed on results, even as management pointed to a record backlog and new product activity as signs of future growth. President and CEO Mike Manna said the company